BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19167214)

  • 1. Improving the efficacy of cancer immunotherapy.
    Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Håkansson L
    Eur J Cancer; 2009 May; 45(8):1424-31. PubMed ID: 19167214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell based cancer vaccines: regulatory and commercial development.
    Copier J; Ward S; Dalgleish A
    Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer vaccines and immunotherapies: emerging perspectives.
    Henderson RA; Mossman S; Nairn N; Cheever MA
    Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current status and future perspective of cancer vaccine development].
    Sasada T; Itoh K
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges for cancer vaccine development.
    Tabi Z; Man S
    Adv Drug Deliv Rev; 2006 Oct; 58(8):902-15. PubMed ID: 16979786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oncoimmunology: some fundamental problems of cancer immunotherapy].
    Nedospasov SA; Kuprash DV
    Mol Biol (Mosk); 2007; 41(2):355-68. PubMed ID: 17514902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technical challenges facing therapeutic cancer vaccines.
    Ward S; Copier J; Dalgleish A
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):168-77. PubMed ID: 18283604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical results of vaccine therapy for cancer: learning from history for improving the future.
    Choudhury A; Mosolits S; Kokhaei P; Hansson L; Palma M; Mellstedt H
    Adv Cancer Res; 2006; 95():147-202. PubMed ID: 16860658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New frontiers in cell-based immunotherapy of cancer.
    D'Elios MM; Del Prete G; Amedei A
    Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological aspects of cancer chemotherapy.
    Zitvogel L; Apetoh L; Ghiringhelli F; Kroemer G
    Nat Rev Immunol; 2008 Jan; 8(1):59-73. PubMed ID: 18097448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC1 as a target antigen for cancer immunotherapy.
    Acres B; Limacher JM
    Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant viral vectors: cancer vaccines.
    Harrop R; John J; Carroll MW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):931-47. PubMed ID: 17030074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.
    Fournier P; Schirrmacher V
    Expert Rev Vaccines; 2009 Jan; 8(1):51-66. PubMed ID: 19093773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising particle-based vaccines in cancer therapy.
    Xiang SD; Scalzo-Inguanti K; Minigo G; Park A; Hardy CL; Plebanski M
    Expert Rev Vaccines; 2008 Sep; 7(7):1103-19. PubMed ID: 18767957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
    Herberman RB; Pearce HL; Lippman SM; Pyenson BS; Alberts DS
    Cancer Res; 2006 Dec; 66(24):11540-9. PubMed ID: 17158189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy: bewitched, bothered, and bewildered no more.
    Steinman RM; Mellman I
    Science; 2004 Jul; 305(5681):197-200. PubMed ID: 15247468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.